Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Consumer Staples Select Sector SPDR Fund — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B), while Consumer Staples Select Sector SPDR Fund trades at $87.29 (market cap $14.73B). The key difference: Consumer Staples Select Sector SPDR Fund is far larger — about 2.9× Travere Therapeutics Inc. Common Stock's market cap, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Consumer Staples Select Sector SPDR Fund for 73 Days on average.
| TVTX | XLP | |
|---|---|---|
Market Cap | $5.02B | $14.73B |
Volume | 2,060,842 | 14,288,954 |
Sector | Health | — |
52-Week High | $67.52 | $90.00 |
52-Week Low | $26.79 | $75.61 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $5.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
XLP trades at $84.19, down 0.26% on the day, with a bullish technical outlook supported by moving averages and ADX signals. Analyst consensus is unanimously positive with 100% buy ratings. Recent news highlights its competitive expense ratio and defensive appeal amid market volatility, with strong performance relative to discretionary sectors in 2026.
The ETF's low costs and sector resilience underpin a favorable outlook, though overbought RSI levels and interest rate sensitivity pose near-term risks. Institutional favor and dividend stability offer long-term value, but macroeconomic pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
